Furthermore, injection of anti‐PD1 antibody with FcγR‐blocking antibody completely suppresses tumour growth in all mice whereas the response to a single anti‐PD1 treatment varies among animals,51 suggesting that targeting the interaction of Fc receptors in TAM with the Fc region of checkpoint blocking antibodies can improve the therapeutic efficacy of checkpoint inhibitors. The gene discussed is FCGR2A; the disease is neoplasm.